Table 1.
General characteristics of the study population.
| Characteristic | CMVR cases (n = 37) | Controls (n = 303) | p value |
|---|---|---|---|
| Recipient age-yr | 28 (6–51) | 27 (6–58) | 0.183∧ |
| Recipient female sex, n (%) | 12 (32.4) | 141 (46.5) | 0.104# |
| Interval from SAA diagnosis to HSCT (mth, range) | 11 (1–240) | 3 (1–240) | 0.209∧ |
| Failure of prior immunosuppressive therapy, n (%) | 6 (16.2) | 73 (24.1) | 0.459# |
| History of heavy transfusion, n (%) | 21 (56.7) | 121 (39.9) | 0.051# |
| Donor female sex, n (%) | 14 (37.8) | 117 (38.6) | 0.927# |
| Infusion cell dose | |||
| mononuclear cell (×108/kg), median (range) | 11.1 (8.9–12.9) | 5.4 (1.9–12.3) | 0.665∧ |
| CD34 cells (×106/kg), median (range) | 10.9 (6.7–16.8) | 4.6 (1.7–10.1) | 0.571∧ |
| EBV infection, n (%) | 19 (51.4) | 47 (15.5) | <0.0001# |
| Varicella-zoster virus infection, n (%) | 6 (16.2) | 43 (14.2) | 0.741# |
| Hepatitis B and C virus infection, n (%) | 8 (21.6) | 56 (18.5) | 0.645# |
| Grade 3 and 4 acute GVHD, n (%) | 6 (16.2) | 72 (23.7) | 0.312# |
| Chronic GVHD, n (%) | 7 (18.9) | 39 (22.8) | 0.310# |
| Rituximab therapy, n (%) | 17 (46.0) | 17 (5.6) | <0.0001# |
| Basiliximab therapy, n (%) | 2 (5.4) | 10 (3.3) | 0.512# |
| Donor type, n (%) | |||
| MSD | 3 (8.1) | 105 (34.7) | 0.001# |
| Alternative donor (HID and URD) | 34 (91.9) | 198 (65.3) | |
| Conditioning regimens, n (%) | |||
| CY + ATG | 0 (0) | 20 (6.6) | 0.257# |
| FCA | 15 (40.5) | 89 (29.4) | |
| BU + CY + ATG | 15 (40.5) | 140 (46.2) | |
| PTCy + ATG | 7 (19.0) | 54 (17.8) |
CMVR, cytomegalovirus retinitis; HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; MSD, human leukocyte antigen-matched sibling donor; HID, haploidentical donor; URD, unrelated donor. The following conditioning regimens were administered to the patients in our study: cyclophosphamide at 50 mg/kg/day for four days and anti-thymocyte globulin at 2.5 mg/kg/day for four days (CY + ATG); fludarabine at 30 mg/m2/day for four days, cyclophosphamide at 40 mg/kg/day for four days and anti-thymocyte globulin at 2.5 mg/kg/day for four days (FCA); busulfan at 3.2 mg/kg/day for two days, cyclophosphamide at 50 mg/kg/day for four days and anti-thymocyte globulin at 2.5 mg/kg/day for four days (BU + CY + ATG), fludarabine at 30 mg/m2/day for four days, cyclophosphamide at 40 mg/kg/day for four days (two days before transplant and two days post-transplant) and anti-thymocyte globulin at 2 mg/kg/day for three days (PTCy + ATG). For MSD HSCT patients, CY + ATG and FCA conditionings were applied. For URD HSCT patients, FCA conditioning was applied. For HID HSCT patients, BU + CY + ATG and PTCy + ATG conditioning were applied. ∧T-test; #chi-square.